⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EXEL News
Exelixis Inc
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
businesswire.com
EXEL
Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain
globenewswire.com
ALNY
SAIL
EXEL
Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain
globenewswire.com
ALNY
SAIL
EXEL
Assisted Reproductive Technology Market Set to Reach $6.02 Billion by 2030 | MarketsandMarkets™
globenewswire.com
COO
THO
TMO
EXEL
Head and Neck Squamous Cell Carcinoma Market Forecast to 2030 & 2035
globenewswire.com
EXEL
MRK
PFE
BMY
AZN
NCCN Foundation Announces Annual Awards to Support Future Leaders for Cancer Innovation
prnewswire.com
EXEL
MRK
PFE
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More
globenewswire.com
MRK
EXEL
PFE
BMY
AZN
NVS
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry
globenewswire.com
PFE
NVS
EXEL
BMY
AMRX
JNJ
$1.59 Billion PD-1 Resistant Head and Neck Cancer Market Analysis Report 2026: Size, Growth, and Segmentation Insights to 2030
globenewswire.com
CVM
EXEL
MRK
PFE
AZN
RPRX
Colorectal Cancer Advocates Urge Congress to Fund New Research
globenewswire.com
EXAS
EXEL
GSK
GH
ISRG
MRK
NTRA
PFE